###### Strengths and limitations of this study

-   This systematic review provides an up-to-date summary of recently published randomised control trials and unpublished data not included in other systematic reviews and meta-analysis.

-   A broad range of outcomes that clinicians consider during medical decision-making are analysed.

-   This systematic review is rigorous in its design, methodology and analyses with a prepublished protocol.

-   The inclusion of only randomised control trials minimises the bias associated with observational studies in order to clearly evaluate the effects of levothyroxine treatment in pregnant women with subclinical hypothyroidism.

-   Only three trials were identified for inclusion.

Introduction {#s1}
============

Subclinical hypothyroidism, generally defined as a thyroid stimulating hormone (TSH) value greater than the upper limit of the reference range with a normal free thyroxine (free T4) and no symptoms of hypothyroidism, is a common biochemical finding in pregnancy, occurring in more than 25% of pregnant women (depending on the assay and reference ranges used).[@R1] It must be noted that the diagnostic criteria for subclinical hypothyroidism in pregnancy have changed over the years and vary between countries. TSH cut-offs for subclinical hypothyroidism in pregnancy are heterogeneous, ranging from 2.5 mU/L,[@R2] to above the 95% ile CI for the population examined and assay used, or 4 mU/L.[@R4]

To date, observational studies of variable methodological quality have found inconsistent associations, (positive, negative and no associations) between subclinical hypothyroidism in pregnancy and adverse obstetrical outcomes[@R5] including miscarriage, fetal death, preterm delivery,[@R6] gestational diabetes, gestational hypertension, eclampsia, placental abruption, low birth weight, 5 min Apgar score \<7[@R7] and lower childhood IQ.[@R8] As a result, despite a paucity of high-quality randomised controlled trials (RCTs) of levothyroxine replacement therapy, many health organisations have advocated for levothyroxine replacement therapy for women with subclinical hypothyroidism diagnosed in pregnancy.[@R4] These recommendations are further supported by an underlying belief that levothyroxine therapy is physiologic and, thus is benign. Emerging data challenge this belief due to the demonstration of increased risks of harms associated with levothyroxine replacement and/or elevated free T4 (even in the subclinical hyperthyroid range) in pregnancy including: increased risks of pre-eclampsia,[@R10] small for gestational age neonates,[@R11] preterm delivery,[@R6] gestational diabetes[@R6] and, in fact, lower IQ.[@R9]

Observational studies of subclinical hypothyroidism in pregnancy have suggested two main underlying hypotheses for the association of subclinical hypothyroidism diagnosed in pregnancy and adverse pregnancy outcomes. It is important to emphasise that observational studies cannot prove causation, but rather associations. The first hypothesis is that subclinical hypothyroidism directly causes pregnancy complications through altered physiological mechanisms. Since untreated neonatal hypothyroidism is a well-established cause of impaired childhood neurodevelopment, it has been hypothesised that untreated maternal subclinical hypothyroidism may adversely impact fetal brain development. Prior to fetal production of thyroid hormone (onset at 18 weeks gestation), the only fetal source of thyroid hormone is from transplacental cross of maternal thyroid hormone.[@R12] Animal studies suggest the importance of thyroid hormone in fetal development of the central nervous system.[@R12] It is also hypothesised that subclinical hypothyroidism may impair proper uteroplacental development resulting in placental insufficiency, thereby causing adverse obstetrical outcomes. Conversely, the second hypothesis suggests that an impaired uteroplacental unit early in pregnancy directly leads to both aberrations in maternal thyroid function tests as well as pregnancy complications. In the first setting, levothyroxine therapy for subclinical hypothyroidism in pregnancy is thought to improve clinical outcomes. However, in the latter setting, levothyroxine therapy for treatment of subclinical hypothyroidism would not improve pregnancy outcomes due to a different underlying pathophysiology.

Given the lack of information about the rate of spontaneous resolution and natural history of untreated subclinical hypothyroidism in pregnancy, as well as the limitations of observational studies which do not establish causation, the best available evidence to guide clinical decision-making is RCTs of levothyroxine therapy in women with subclinical hypothyroidism diagnosed in pregnancy. As such, the objective of this review is to systematically evaluate all RCTs of levothyroxine therapy in pregnancy (compared with placebo or no treatment) to determine whether pregnant women with subclinical hypothyroidism receive benefit from levothyroxine on important obstetrical, neonatal or childhood neurodevelopmental outcomes (specifically IQ).

Methods {#s2}
=======

We performed a systematic review and meta-analysis as outlined in the PROSPERO published protocol. Results are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@R13]

Study question {#s2a}
--------------

This review examined the following question: 'In women with subclinical hypothyroidism diagnosed in pregnancy, does treatment with levothyroxine versus control (either placebo or no treatment) influence obstetrical, neonatal or childhood outcomes?'

Study eligibility criteria {#s2b}
--------------------------

Studies that met all the following criteria were included in this review: (1) pregnant women diagnosed with subclinical hypothyroidism (by any prespecified study definition); (2) randomised to levothyroxine versus control (ie, placebo or no treatment); (3) reported obstetrical, neonatal and/or childhood neurodevelopmental outcomes; (4) reported results in either English or French and (5) published from 1980 to 25 January 2018. The publication date of 1980 was specifically chosen to coincide with the availability of more sensitive TSH assays to minimise classification bias for subclinical hypothyroidism.[@R14]

Study outcomes {#s2c}
--------------

The following clinically relevant obstetrical, neonatal and childhood outcomes were prespecified. Obstetrical outcomes included: miscarriage, gestational hypertension, pre-eclampsia, preterm delivery and mode of delivery. Neonatal outcomes included: admission to neonatal intensive care unit (NICU), birth weight and gestational age at delivery (weeks). Childhood outcomes included: IQ and any other validated measures of childhood neurodevelopment.

Search strategy {#s2d}
---------------

The search strategy was developed in consultation with a trained medical librarian. The search strategy was composed of the following terms: Hypothyroidism/or hypothyroidism.mp, Pregnancy/or pregnanc\* or pregnant, Thyroxine/or thyroxine.mp or synthroid.mp or lt4.mp, and was modified according to search headings for each database. Each term was separated by the Boolean term 'AND'. The search was conducted using the Scottish Intercollegiate Guidelines Network filters for RCTs where possible.[@R16] The search was limited to human studies. The full search strategy is provided in online [supplementary table 1](#SP1){ref-type="supplementary-material"}.
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Data sources and searches {#s2e}
-------------------------

The following databases were searched in duplicate on 25 January 2018 from inception of the database: Medline, EMBASE, CINAHL, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials. In addition, references of included articles were hand-searched in duplicate to identify additional articles for inclusion. Experts in the field of endocrinology in pregnancy were consulted for potential additional articles. ClinicalTrials.gov was searched for active studies.

Study selection {#s2f}
---------------

Study selection was completed in two separate stages by two independent reviewers following PRISMA guidelines. In the first step, titles and abstracts of all citations retrieved by the search were reviewed for eligibility. In the second step, all citations deemed eligible at the title and abstracts stage were reviewed for eligibility in a full-text format. Reasons for exclusion were recorded. Agreement was recorded at each stage and reported as a kappa statistic. Disagreements between reviewers were resolved by consensus and by consultation with a third independent reviewer when necessary.

Data collection process {#s2g}
-----------------------

Two reviewers independently extracted relevant study information in duplicate using standardised data extraction forms. Extracted data elements included: study characteristics, study definition of subclinical hypothyroidism, baseline participant characteristics, and obstetrical, neonatal and childhood neurodevelopmental outcomes (ie, IQ or other validated neurodevelopmental outcomes). Data management was performed using Microsoft Excel.

Risk of bias assessment {#s2h}
-----------------------

Each reviewer assessed study quality independently using the Cochrane Risk of Bias Tool (Modified) for Quality Assessment of Randomised Controlled Trials.[@R17] This tool assesses seven methodological domains and provides a summary measure of bias for each study categorised as 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'.

Data synthesis and analysis {#s2i}
---------------------------

Meta-analyses were performed using random-effect models for continuous outcomes relating to harms and benefits of treatment where there was sufficient data. Dichotomous outcomes were meta-analysed using a Mantel-Haenszel method. Risk ratios and 95% CIs were calculated. A prespecified meta-analysis of summary measures of the effect size for childhood IQ was planned. Prespecified sensitivity analyses were planned to evaluate the effects of important clinical predictors on clinical outcomes (eg, timing of initiation of levothyroxine therapy in pregnancy, dose of levothyroxine, duration of treatment, duration of follow-up, definition of subclinical hypothyroidism, treatment strategy (ie, treat to target vs fixed dose), race or ethnicity, iodine status, body mass index, method of IQ measurement, study quality and date of publication (ie, to reflect local practice)). Statistical heterogeneity was quantified using I^2^ statistics where appropriate, where I^2^\>50% represents moderate and I^2^\>75% represents substantial heterogeneity across studies. Statistical analyses were performed using Review Manager (V.5.3, The Cochrane Collaboration, Copenhagen, Denmark).

Patient and public involvement {#s2j}
------------------------------

Patient involvement was not specifically sought for this study. The authors have managed a large number of women screened for subclinical hypothyroidism in pregnancy. As experienced clinicians, we recognise the burden of levothyroxine implementation includes additional laboratory testing during pregnancy and post partum and extra physician contacts as well as daily medication ingestion during pregnancy.

Results {#s3}
=======

As outlined in [figure 1](#F1){ref-type="fig"}, of the 342 citations identified by the sensitive search strategy, nine citations were identified for full-text review.[@R18] Three trials (n=1837 pregnant women) met all eligibility criteria and thus were included in the qualitative and quantitative analyses.[@R18] An additional study by Hales *et al* [@R26] reported a longer 9-year follow-up analysis of one of the included trials.[@R19] The original trial data were included in the full analysis because the reporting and follow-up in the original trial were much more complete. However, we report and discuss the 9-year follow-up data[@R26] because it is the longest duration of follow-up of offspring of women with subclinical hypothyroidism in pregnancy ever reported. The kappa statistic for inter-rater agreement for the title and abstract review was 0.70 (95% CI 0.45 to 0.95) and for the full-text review was 0.57 (95% CI 0.10 to 1.00).

![PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](bmjopen-2018-022837f01){#F1}

Study characteristics {#s3a}
---------------------

Included study characteristics are summarised in [table 1](#T1){ref-type="table"}. One trial compared levothyroxine to placebo[@R18] and two compared with no treatment.[@R19] One trial randomised women to thyroid function screening during pregnancy (followed by levothyroxine treatment if a diagnosis of subclinical hypothyroidism was found) versus thyroid function screening of stored frozen maternal blood after delivery.[@R19] The study definitions of subclinical hypothyroidism differed in each trial ([table 1](#T1){ref-type="table"}). One study included women with thyroid peroxidase (TPO) antibodies,[@R18] one excluded women with TPO antibodies[@R20] and the last study did not specify TPO antibody status.[@R19]

###### 

Characteristics of included randomised controlled trials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study author (year)           Country        N     Intervention\                                                  Comparator     Definition of subclinical hypothyroidism              Percentage of trial subjects with TPO antibody ≥50 IU/mL   Clinical outcomes
                                                     levothyroxine                                                                                                                                                                                  
  ----------------------------- -------------- ----- -------------------------------------------------------------- -------------- ----------------------------------------------------- ---------------------------------------------------------- -------------------------------------
  Casey *et al* [@R18] (2017)   USA            677   Treatment of subclinical hypothyroidism or hypothyroxinaemia   Placebo        TSH \>3.00 then \>4.00 mU/L and a normal free T4      33%                                                        Childhood IQ and pregnancy outcomes

  Nazarpour *et al* [@R20]\     Iran           366   Treatment of subclinical hypothyroidism                        No treatment   TSH 2.5--10 mU/mL and a normal free thyroxine index   0                                                          Pregnancy outcomes
  (2018)                                                                                                                                                                                                                                            

  Lazarus *et al* [@R19]\       UK and Italy   794   Thyroid screening plus treatment if criteria met               No treatment   TSH \>97.5th centile and/or free T4 \<2.5th centile   Not reported                                               Childhood IQ
  (2012)                                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TPO, thyroid peroxidase; TSH, thyroid stimulating hormone; T4, thyroxine.

Participant characteristics {#s3b}
---------------------------

Baseline participant characteristics are summarised in [table 2](#T2){ref-type="table"}. Gestational age at randomisation was highest for Casey *et al*, with a mean time of randomisation of approximately 16 weeks gestation. Both Nazarpour *et al* and Lazarus *et al* randomised participants at an average gestational age closer to 12 weeks. Specifically, in the Nazarpour *et al* trial, 71% of women in the levothyroxine arm were recruited prior to 14 weeks gestation and in Lazarus *et al* 62% of women in the treatment arm were started on levothyroxine prior to 14 weeks gestation.

###### 

Baseline participant characteristics in included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study author (year)     Maternal age (years)   Body mass index (kg/m^2^)   Baseline TSH (mU/L)   Urinary iodine (μg/L)   Gestational age at trial entry (weeks)                                                                                  
  ----------------------- ---------------------- --------------------------- --------------------- ----------------------- ---------------------------------------- --------------------- --------------------- --------------------- ------------ ------------
  Casey\                  27.7±5.7               27.3±5.7                    28.1±6.4              28.2±6.4                4.5\                                     4.3\                  199\                  196\                  16.6±3.0 µ   16.7±3.0 µ
  *et al* [@R18] (2017)                                                                                                    (95% CI 4.4 to 4.7)                      (95% CI 4.2 to 4.5)   (95% CI 184 to 238)   (95% CI 172 to 229)                

  Nazarpour\              27.0±5.34              26.9±4.74                   25.8±4.95             26.0±4.64               3.8\                                     3.6\                  140\                  123\                  11.4±4.1 α   12.2±4.3 α
  *et al* [@R20] (2018)                                                                                                    (IQR 2.8--4.8)                           (IQR 3.1--4.2)        (IQR 89-- 219)        (IQR 86-- 220)                     

  Lazarus\                30±5.4                 31±5.3                      Not reported          UK: 3.8\                UK: 3.2\                                 Not reported          12^+3^\               12^+3^\                            
  *et al* [@R19] (2012)                                                                            (IQR 1.5--4.7)\         (IQR 1.2--4.2\                                                 (11^+6^, 13^+6^) \#   (11^+6^, 13^+5^) \#                
                                                                                                   Turin: 3.1\             Turin: 2.4\                                                                                                             
                                                                                                   (IQR 1.3--4.0)          (IQR 1.3-- 3.9)                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results presented as either means±SD or as median (with IQR or 95% CI) as described, LT4: levothyroxine.

Control, Placebo (Casey *et al*), no treatment (Nazarpour, Lazarus), µ=at randomisation, α=at first visit, \# at screening.

TSH, thyroid stimulating hormone.

Risk of bias assessment {#s3c}
-----------------------

Study quality and risk of bias assessments are presented in [figures 2 and 3](#F2 F3){ref-type="fig"}. Only one trial[@R18] was considered 'low risk' in all seven domains of the Cochrane Collaboration's tool for risk of bias assessment. The Lazarus trial randomised participants to either immediate screening and treatment for subclinical hypothyroidism or delayed screening. Specifically, women randomised to immediate screening had their thyroid function assessed at approximately 12 weeks gestation. If the participants met criteria for subclinical hypothyroidism, they were started on levothyroxine. Women randomised to delayed screening had a blood sample taken at the same gestational age, but stored for analysis after delivery. Given that the results were not available until after pregnancy, no placebo was used. Thus, the Lazarus trial scored high risk for performance bias, unclear risk of detection bias, since they did not report if outcome assessment was blinded, and low risk of bias in the remaining five domains.

![Risk of bias assessment.](bmjopen-2018-022837f02){#F2}

![Trial quality assessment.](bmjopen-2018-022837f03){#F3}

Maternal, obstetrical and neonatal outcomes {#s3d}
-------------------------------------------

Data from two trials[@R18] including a total of 1043 women allowed for meta-analysis of the following five outcomes: preterm delivery \<37 weeks gestation, gestational age at delivery, placental abruption, NICU admission and head circumference ([figure 4](#F4){ref-type="fig"}). There were no significant differences between levothyroxine versus control (ie, placebo or no treatment) for any of these outcomes. Meta-analysis for all outcomes had little heterogeneity (I^2^=0%) except for placental abruption (I^2^=73%), which demonstrated moderate heterogeneity between studies.

![Results of meta-analysis of effects of treatment with levothyroxine on clinical outcomes, (A) preterm delivery \<37 gestational weeks, (B) gestational age at delivery, (C) neonatal intensive care unit admission, (D) placental abruption, (E) head circumference.](bmjopen-2018-022837f04){#F4}

Additional comparisons reported in a single trial that could not be meta-analysed included stillbirth[@R20] (0 for both arms; p=not reported); stillbirth or miscarriage[@R18] (1% vs 2% for levothyroxine and placebo, respectively; p=0.36); gestational diabetes[@R18] (7% both arms; p=0.66); gestational hypertension[@R18] (10% vs 11% for levothyroxine and placebo, respectively; p=0.69); pre-eclampsia[@R18] (6% both groups; p=0.76) and neonatal death[@R18] (0 vs \<1% for levothyroxine and placebo, respectively; p=0.5).

Childhood outcomes {#s3e}
------------------

Two trials[@R18] reported childhood IQ and other commonly used and validated measures of childhood neurodevelopment. The authors of the Casey *et al* trial provided additional unpublished data on IQ (mean and SD) allowing for inclusion in the meta-analysis ([figure 5](#F5){ref-type="fig"}). The meta-analysis for childhood IQ showed no significant difference between levothyroxine versus control ([figure 5A](#F5){ref-type="fig"}) (mean difference −0.69, 95% CI −2.15 to 0.78; p=0.36, I^2^=0%). One trial initiated levothyroxine at a mean gestational age of 16.7 gestational weeks and reported median IQ at 5 years.[@R18] The other trial initiated levothyroxine at median of 13 weeks and 3 days and reported mean IQ at 3 years.[@R19] Both studies showed no impact of levothyroxine on Child Behaviour Checklist T-Scores ([table 3](#T3){ref-type="table"}). Furthermore, both trials found that childhood IQ and Child Behaviour Checklist T-Scores[@R18] were within the normal range in both levothyroxine and control arms of their trials ([table 3](#T3){ref-type="table"}). There were no differences in IQ in the Lazarus *et al* trial based on the components of their study definition of subclinical hypothyroidism that included women with either a TSH \>97.5th centile or those with hypothyroxinaemia (free T4 \<2.5th centile). Specifically, women with TSH \>97.5th centile alone (n=428) had similar IQ's in their children (100.4±13.7 vs 100.7±13.0 for intervention and control arms, respectively; p=0.82) and women with a free T4 \<2.5th also had similar IQ's between study arms (97.8±12.7 vs 99.2±13.3 for intervention and control arms, respectively; p=0.28).[@R19]

###### 

Neurodevelopmental outcomes of studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)\                    Childhood IQ    Child Behaviour Checklist T-Score at 3 years \^   Child Behaviour Checklist\                                                 
  \[Childhood age\]                                                                                  at 5 years                                                                 
  -------------------------------- --------------- ------------------------------------------------- ---------------------------- ---------------------- ---------------------- ----------------------
  Casey *et al* [@R18] (2017)\     n=311\          n=314\                                            n=306\                       n=309\                 n=314\                 n=313\
  \[5 years\]                      95.9±15.7^\#^   96.4±14.8^\#^                                     46 (95% CI 45 to 48)         46 (95% CI 45 to 48)   44 (95% CI 43 to 46)   44 (95% CI 42 to 46)

  Lazarus *et al* [@R19] (2012)\   n=390\          n=404\                                            n=390\                       n=404\                                        
  \[3 years\]                      99.2±13.3       100.0±13.3                                        44.4±12.4                    45.1±13.6                                     

  Hales *et al* [@R26] (2018)\     n=119\          n=98\                                                                                                                        
  \[9 years\]                      101.8±12.0      102.3±13.3                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results presented as either means±SD or as median (with IQR or 95% CI) as described. ^\#^ unpublished data provided from the Casey et al trial, \^ score of \< 60 was defined as normal range.

![Results of meta-analysis of effects of treatment with levothyroxine on childhood IQ (A) childhood IQ at 3 and 5 years, (B) sensitivity analysis of childhood IQ at 5 and 9 years (note all three studies were not combined because the Lazarus and Hales trials were from the same cohort).](bmjopen-2018-022837f05){#F5}

Lazarus *et al* reported no significant differences in the Behaviour Rating Inventory of Executive Function (preschool version) scale T-scores at 3 years (median 40, IQR 47--55\] and 40, IQR 47--55; p=0.59 for levothyroxine and control, respectively) and normal scores in both groups.[@R19] Casey *et al* found no significant differences between levothyroxine and placebo arms across several additional neurodevelopmental assessment tools including: Bayley-III scores, Differential Ability Scales-II scores and Conners' Rating Scales-Revised attention deficit hyperactivity disorder score.[@R18]

Finally, the follow-up study of the Lazarus *et al* trial demonstrated no impact of subclinical hypothyroidism in pregnancy (using the original trial definition (ie, TSH \> 97.5th centile and/or a free T4 \<2.5th centile)) on childhood IQ[@R26] at 9 years of age; 101.76±12.04 (n=119) vs 102.31±13.28 (n=98) for the children of mothers treated with levothyroxine and untreated, respectively. There was also no IQ difference after 9 years of follow-up among children of mothers who only had TSH \>97.5th centile (103.06±12.20 (n=63) vs 104.80±12.94 (n=51) levothyroxine and untreated, respectively). When a sensitivity analysis was done by substituting the 9-year follow-up data for the 3-year follow-up data from this same cohort the result remained unchanged and showed no impact of levothyroxine on childhood IQ (mean difference −0.5, 95% CI −2.46 to 1.46; p=0.62, I^2^=0%) ([figure 5B](#F5){ref-type="fig"}).

Potential harms associated with treatment of subclinical hypothyroidism {#s3f}
-----------------------------------------------------------------------

Lazarus *et al* reported that 10% of women in their levothyroxine arm had their dose of levothyroxine lowered due to either biochemical hyperthyroidism (ie, a very low TSH or a high free T4 level) or clinical symptoms of hyperthyroidism (ie, palpitations) associated with levothyroxine overtreatment.[@R19] The other two trials did not report similar data. The Casey *et al* trial reported similar rates of anticipated adverse events between treatment arms; 15.1% vs 12.2% in the levothyroxine and placebo arms, respectively.[@R18] Unanticipated adverse events in the levothyroxine arm were: maternal chest/abdominal pain (n=1), irregular fetal heart (n=1), autism spectrum (n=1) and severe hearing loss (n=1) whereas the placebo arm reported Hashimoto's thyroiditis (n=1) and intrauterine growth restriction (n=1).[@R18] Nazarpour *et al* [@R20] did not report adverse events.

Sensitivity analysis {#s3g}
--------------------

Our prespecified sensitivity analysis could not be performed because of the small number of studies reporting the specific data. One trial evaluated the TSH cut-off of ≥4 mU/L vs \<4 mU/L in a post hoc analysis.[@R20] Among women with a TSH ≥4 mU/L, there was a lower proportion of preterm delivery in the levothyroxine treated group compared with the untreated group (7.3% vs 19%, respectively; p value not reported). Whereas in women with a TSH \<4 mU/L, levothyroxine treatment was associated with a higher preterm delivery rate compared with untreated women (12.8% vs 8.3%, respectively; p value not reported). We could not perform a sensitivity analysis as the number of women who had a TSH ≥4 mU/L was not reported in this post hoc analysis. Only three studies met our inclusion criteria, which all had negative results relating to the primary outcome, therefore, a formal assessment of publication bias was not done.

Discussion {#s4}
==========

This systematic review and meta-analysis of RCTs of levothyroxine treatment in women with subclinical hypothyroidism diagnosed in pregnancy demonstrated no evidence of benefit of levothyroxine treatment across a wide range of prespecified maternal, obstetrical and neonatal outcomes and childhood IQ. Importantly, this review found no evidence of benefit of levothyroxine treatment during pregnancy on childhood IQ and neurodevelopment measures at 3, 5 or 9 years of follow-up. These findings challenge the current clinical practice guidelines which recommend the use of levothyroxine therapy for treatment of women with subclinical hypothyroidism diagnosed in pregnancy.[@R4] As outlined below, these results also question the recommendations of levothyroxine therapy earlier in pregnancy than occurred in the available RCTs and at lower TSH thresholds among women who are TPO antibody positive.[@R4]

This review found that the timing of initiation of levothyroxine therapy was not significantly associated with childhood IQ. First, in the Lazarus *et al* trial,[@R19] 62% of women were started on levothyroxine at less than 14 weeks gestation. There was no difference in childhood IQ among women who were started on levothyroxine prior to 14 weeks gestation compared with no treatment (98.7±14.1 vs 100.00±13.3 levothyroxine vs control, respectively; p=0.28), although this study was underpowered to examine this difference.[@R19] Second, a prespecified subgroup analysis in the Casey *et al* trial found no significant interaction for childhood IQ by gestational weeks at randomisation[@R18] but likely was also underpowered to answer this question. Third, the Nazarpour *et al* trial entry visit was at the earliest gestation, a mean of 11.4 (SD ±4.1) weeks. This trial also showed no impact of early timing of initiation of levothyroxine therapy. Given the above findings, it appears implausible that treatment at an earlier gestational age may improve childhood IQ, particularly given the finding of normal childhood IQ up to 9 years later.[@R18] Furthermore, childhood IQ was not different between children of mothers with normal thyroid function and those with subclinical hypothyroidism after 9 years of follow up.[@R26]

Some have hypothesised that levothyroxine treatment prepregnancy might be more appropriate since that might affect placentation and very early fetal neurodevelopment. The T4 life[@R29] and TABLET (Thyroid AntiBodies and LEvoThyroxine) trials,[@R30] results of which are yet to be reported, are assessing the impact of prepregnancy levothyroxine on pregnancy outcomes in TPO antibody positive women. However, these trials include euthyroid women only. Interestingly, a recent large randomised control trial of preconception levothyroxine in TPO antibody positive women with TSH levels between 0.5 and 4.78 mIU/L undergoing in vitro fertilisation showed no benefits of levothyroxine on pregnancy, miscarriage, live birth or preterm delivery rates[@R31] suggesting no benefit of levothyroxine replacement on placental development.

Based on their observational studies, some investigators[@R27] have raised the possibility of a synergistic association of subclinical hypothyroidism and TPO antibody positivity to adversely influence obstetrical and childhood outcomes. The trials in our review that included thyroid antibody positive women[@R18] were not specifically powered to analyse the results by maternal antibody status. The Casey study, however, had a large proportion of participants with TPO antibody positivity (33% of women with subclinical hypothyroidism)[@R33] and found no association between TPO antibodies and childhood IQ in either study arm.[@R18] Furthermore, in addition to their published trial results, Casey *et al*'s published abstract of their trial demonstrated no impact of TPO status on pregnancy loss or stillbirth, preterm birth, pre-eclampsia or placental abruption.[@R33] The Lazarus *et al* trial[@R19] did not specifically report thyroid antibody status, nor was it part of their trial exclusion criteria. Based on other studies of reproductive age women, it is reasonable to assume that at least 14% of women in this trial would have had positive antithyroid antibodies.[@R18] Thus, trial evidence to date shows no benefit of treatment with levothyroxine for women with subclinical hypothyroidism who are TPO antibody positive during pregnancy.

The included RCTs did not consistently report harms of levothyroxine treatment and were also of inadequate sample size to fully examine this association. This is important as large observational studies of levothyroxine therapy in pregnancy[@R6] as well as high free T4 values in pregnancy[@R10] have found increased risks of gestational diabetes, pre-eclampsia, and small for gestational age[@R6].[@R11] Only the Casey trial[@R18] (n=677) reported these outcomes and found no increase in gestational diabetes, pre-eclampsia and small for gestational age in the levothyroxine arm.[@R18] The only direct harm of levothyroxine found by this review was iatrogenic hyperthyroidism in 10% of the treated women (either biochemical or symptomatic) in the Lazarus trial,[@R19] which used higher dosing of levothyroxine compared with the other trials. Reassuringly, the 9-year follow-up analysis suggests that this oversupplementation with levothyroxine did not have a detrimental effect on childhood IQ[@R26].

None of the included studies examined the cost-effectiveness of treatment with levothyroxine for subclinical hypothyroidism in pregnancy. Given the lack of evidence of benefit of levothyroxine on obstetrical, neonatal and neurodevelopmental outcomes, the costs of healthcare resources associated with screening, therapy and monitoring of subclinical hypothyroidism in pregnancy and post partum must be rigorously evaluated to ensure appropriate healthcare resource allocation.

This systematic review has several strengths. It provides an up-to-date summary of recently published RCTs not included[@R20] in other systematic reviews and meta-analyses[@R5] and it addresses a broad range of clinical outcomes that clinicians consider during medical decision-making. This systematic review is rigorous in its design, methodology and analyses. Furthermore, the inclusion of only RCTs minimises the bias associated with observational studies[@R35] in order to clearly evaluate the effects of levothyroxine treatment in pregnant women with subclinical hypothyroidism.

Our review's findings must be interpreted in the context of the study's limitations. First, this review limited the search to trials published in English or French. This is unlikely to have biased the results as the included trials were conducted across several countries (North America, Europe and the Middle East) and included mixed racial populations with differing maternal iodine status which also did not impact results ([table 1](#T1){ref-type="table"}). Thus, our study's results are likely generalisable to a broad range of populations. Second, our review limited study selection to published trials (a priori). These eligibility criteria were specifically chosen to ensure high-quality results, though limits the ability to use data from the Casey and Lazarus trials[@R18] that are currently published only in abstract form.[@R24] Of note, the Lazarus abstract also reports no significant differences in obstetrical outcomes among women with subclinical hypothyroidism randomised to levothyroxine compared with untreated women.[@R24] Similarly, analysis of maternal and neonatal outcomes by maternal TPO antibody status in the Casey trial is currently published in abstract form[@R33] and also showed no association of TPO antibody status on maternal outcomes. Once these results are published in full-text format, an updated systematic review will be important. A priori we decided to use random-effects models. Only two studies per outcome were available for meta-analyses so between study variance could not be accounted for accurately. When fixed-effect models (with inverse weighting) were used, the results were the same as those from the random-effects models. Lastly, given the median and IQR or 95% CI of baseline TSH measurements for women enrolled in these trials, it remains difficult to extrapolate these trial findings to women with subclinical hypothyroidism in pregnancy with TSH measurement between 5 and 10 mU/L. Therefore, a trial of women with subclinical hypothyroidism with TSH \>5.0 to \<10.0 mU/L may be warranted.

In summary, data from three randomised trials fail to demonstrate any evidence of benefit of treating subclinical hypothyroidism in pregnancy on important obstetrical, neonatal, childhood IQ and neurobehavioural outcomes. Current trial evidence does not support the treatment of subclinical hypothyroidism diagnosed in pregnancy. Given the lack of evidence of benefit of levothyroxine therapy for subclinical hypothyroidism in pregnancy, the treatment and by extension the practice of screening for subclinical hypothyroidism in pregnancy needs careful re-examination.
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